The European Society of Medicine has published an overview titled "Nanofat and HD PRP in Aesthetic Medicine," consolidating current thinking on two of the most widely used regenerative techniques in the aesthetics clinic.

The piece, surfaced via Google News syndication, addresses nanofat — the emulsified, filtered form of autologous fat processed to a liquid consistency for injection — and high-density platelet-rich plasma (HD PRP), a concentrated formulation of the patient's own platelets. Both sit at the intersection of regenerative medicine and aesthetic practice, and both are practitioner-processed: neither arrives as a standardized commercial product, which is precisely why overview literature like this carries weight.

What does this change for clinicians?

Notably, the source material available for this article consists of the publication's title and its publisher — the European Society of Medicine — rather than the full text of the overview itself. That constraint matters, and Derm Field won't speculate beyond it. So this story is best read as a signal of what the society considers worth consolidating right now.

What the title alone tells us is where the editorial attention is going:

• Nanofat: mechanical emulsification of autologous adipose tissue, typically used where structural volume isn't the goal but skin-quality improvement is — the regenerative fraction rather than the filler fraction of fat grafting.
• HD PRP: a higher-concentration platelet preparation, distinct from standard PRP in processing and, proponents argue, in growth-factor payload per milliliter.
• Aesthetic medicine as the frame: the overview is positioned in the aesthetics context, not orthopedics or wound care, where PRP also has a long history.

Why an overview, and why now?

Both techniques share a practical problem: preparation protocols vary from clinic to clinic, from centrifugation settings to filtration steps, and published evidence is scattered across small studies with heterogeneous methods. A society-level overview is the kind of document that attempts to impose order on that scatter — defining terms, summarizing mechanism claims, and, ideally, separating manufacturer and protocol-marketing language from trial data.

That separation is overdue. Autologous preparations escape many of the regulatory pathways that govern manufactured injectables, so claims travel faster than controlled data. Reviews from established medical societies are one of the few mechanisms the field has for triage.

The open questions

For practitioners tracking this space, the questions an overview like this should answer are concrete:

• How is "high density" in HD PRP actually defined — platelet concentration per microliter, or capture efficiency relative to baseline blood counts?
• What particle size and processing parameters distinguish nanofat from microfat, and which indications does that distinction actually change?
• What evidence class — case series, comparative cohorts, randomized trials — supports each claimed indication?

Derm Field will follow up with a detailed assessment once the full text of the European Society of Medicine overview is accessible, including any specific protocol parameters and outcome data the authors report.